Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-12-21
DOI
10.3389/fimmu.2018.03081
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- (2018) Toni K Choueiri et al. LANCET ONCOLOGY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
- (2018) Lei Zhang et al. NEURO-ONCOLOGY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
- (2018) Priyanka C. Iyer et al. Journal for ImmunoTherapy of Cancer
- Emerging strategies for combination checkpoint modulators in cancer immunotherapy
- (2018) Aleksandra Popovic et al. JOURNAL OF CLINICAL INVESTIGATION
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
- (2017) H. Rexer et al. UROLOGE
- Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
- (2017) H. Rexer et al. UROLOGE
- FDA Approves Trastuzumab Biosimilar
- (2017) Cancer Discovery
- Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
- (2017) Xinqi Wu et al. Cancer Immunology Research
- High Endothelial Venules and Other Blood Vessels: Critical Regulators of Lymphoid Organ Development and Function
- (2017) Ann Ager Frontiers in Immunology
- Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
- (2016) Florence T.H. Wu et al. CANCER RESEARCH
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
- (2016) Luuk van Hooren et al. Oncotarget
- VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
- (2016) X. Wu et al. Cancer Immunology Research
- Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention
- (2016) Catherine Sautès-Fridman et al. Frontiers in Immunology
- Targeting the tumor vasculature to enhance T cell activity
- (2015) Evripidis Lanitis et al. CURRENT OPINION IN IMMUNOLOGY
- VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation
- (2015) Hua Huang et al. FASEB JOURNAL
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Intertwined regulation of angiogenesis and immunity by myeloid cells
- (2015) Lee B. Rivera et al. TRENDS IN IMMUNOLOGY
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Trafficking of T Cells into Tumors
- (2014) C. Y. Slaney et al. CANCER RESEARCH
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Control of the Adaptive Immune Response by Tumor Vasculature
- (2014) Laetitia Mauge et al. Frontiers in Oncology
- A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis
- (2013) Massimo Masiero et al. CANCER CELL
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
- (2013) Jonathan Welti et al. JOURNAL OF CLINICAL INVESTIGATION
- An evolving new paradigm: endothelial cells – conditional innate immune cells
- (2013) Jietang Mai et al. Journal of Hematology & Oncology
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Cell Heterogeneity
- (2013) W. C. Aird Cold Spring Harbor Perspectives in Medicine
- Nitric Oxide–Producing Myeloid-Derived Suppressor Cells Inhibit Vascular E-Selectin Expression in Human Squamous Cell Carcinomas
- (2012) Ahmed E. Gehad et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization
- (2012) Lothar C Dieterich et al. JOURNAL OF PATHOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Egfl7 Promotes Tumor Escape from Immunity by Repressing Endothelial Cell Activation
- (2011) S. Delfortrie et al. CANCER RESEARCH
- Enhancement of T-cell-Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer
- (2011) R. P. M. Dings et al. CLINICAL CANCER RESEARCH
- Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not?
- (2011) Katrien De Bock et al. Nature Reviews Clinical Oncology
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling
- (2010) T. Cindrova-Davies et al. CARDIOVASCULAR RESEARCH
- Vessel abnormalization: another hallmark of cancer?Molecular mechanisms and therapeutic implications
- (2010) Katrien De Bock et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Stem cells in tumor angiogenesis
- (2010) Shentong Fang et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer
- (2009) Hendrik-Tobias Arkenau et al. ONCOLOGY
- TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype
- (2008) R. C. A. Sainson et al. BLOOD
- Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer
- (2008) Elise Langenkamp et al. CELL AND TISSUE RESEARCH
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Bevacizumab for the treatment of advanced non-small-cell lung cancer
- (2008) Christian Manegold Expert Review of Anticancer Therapy
- Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells
- (2008) Rachael A. Clark et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
- (2007) Ronald J Buckanovich et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation